Compare Nu Holdings Ltd (NU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Sanofi SA — how do they compare? Nu Holdings Ltd trades at $15.44 (market cap $75.26B), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 6.02% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Sanofi SA for 94 Days on average.
| NU | SNY | |
|---|---|---|
Market Cap | $75.26B | $96.81B |
Volume | 82,363,718 | 2,081,815 |
Sector | Financials | Health |
52-Week High | $18.76 | $52.34 |
52-Week Low | $11.60 | $39.51 |
Typical Hold Time | 53 Days | 94 Days |
Enterprise Value | $97.88B | $116.20B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings trades at $15.38, down 1.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights market volatility around potential acquisition rumors, though the company has denied pursuing a Monzo deal.
The outlook remains positive with analyst consensus favoring Buy ratings (56.52%) and a $16.53 price target suggesting 7.5% upside. Key risks include credit quality concerns from expanding lending operations and high customer concentration. Revenue growth and profitability trends support continued investor interest despite recent earnings misses.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
